MedTrace Logo

Ramipril 10 mg/Day Prevention

NCT01053910 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1012

Last updated 2010-01-22

No results posted yet for this study

Summary

The objective is to investigate the safety of ramipril 10 mg/day used in prevention of cardiovascular events in high-risk patients, including the criteria of the HOPE study.

Conditions

Interventions

DRUG

Ramipril

tablet of Ramipril once daily

Sponsors & Collaborators

Principal Investigators

  • Rezaul Farid Khan, Medical Director · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2005-07-31

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01053910 on ClinicalTrials.gov